logo
Plus   Neg
Share
Email

Informa 10-month Underlying Revenue Rises - Quick Facts

Informa plc (INFMF.PK,INF.L), an Exhibitions, Events, Business Intelligence and Academic Publishing Group, reported Monday that it has continued to perform well, with growth in revenue, adjusted profit, and earnings for the 10-month period to October 31. The full-year performance is on track.

In its trading update, the company said its underlying revenue growth was at 2.8%, ahead of significant, seasonally stronger November/December trading period.

Stephen Carter, Group Chief Executive, said, "After ten months trading in 2019, despite an unpredictable economic/geo-political backdrop, the enlarged Informa Group continues to demonstrate resilience and performance, remaining on track for a sixth consecutive year of growth in underlying revenue, profit, adjusted earnings and cashflow."

The company noted that November and December are significant trading months for the enlarged Informa Group, representing around 20% of annual revenue. November alone is expected to account for more than 350 million pounds.

Despite ongoing economic/geo-political uncertainty, forward pacing for the remainder of 2019 provides reassurance on Group revenue guidance of 3.5% for the year.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
New York Attorney General Letitia James has fled a lawsuit against Vyera Pharmaceuticals and two of its former CEOs, including imprisoned 'Pharma Bro' Martin Shkreli, for illegally monopolizing a life-saving drug Daraprim. The lawsuit seeks a lifetime ban on Shkreli and his business partner Kevin Mulleady working in the pharmaceutical industry. Graco Inc. (GGG) shares were climbing more than 7 percent in morning trade. Monday after market close, the company had reported a surge in the fourth-quarter earnings to $84.8 million from $73.7 million in the prior year. Earnings per share surpassed analysts' estimates. Sales were up 1 percent to $412.3... Strategy of getting multiple indication approvals for the same drug seems to be paying off for AstraZeneca PLC (AZN), in terms of higher likelihood of approval and improved sales. Besides, the company is realizing value from non-core, mature brands to invest in new drugs, which also seems to be working in its favor.
RELATED NEWS
Follow RTT
>